Genetic Signatures

25 DIRECTORS’ REPORT FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021 5 DIRECTORS Name: Nickolaos Samaras Qualifications: BSc (Hons), PhD, MBA, FAIM, FAICD Experience: Dr. Samaras has had over 30 years’ business experience in the global Life Sciences industry and is a recognised and respected industry expert. He has held a number of senior executive level positions in management, marketing, sales, and research and development. His roles have included appointments as Managing Director of Applied Biosystems Pty Ltd (now part of Thermo Fisher), and senior roles with Perkin Elmer and AMRAD Corporation (now part of CSL). Dr. Samaras is an experienced executive, non-executive and Board Chairman, having served on the boards of several biotechnology companies including one that was ASX-listed. For the past 16 years Dr. Samaras has focused his efforts on facilitating the international market expansion of a number of US biotechnology companies and developing commercial revenue channels outside of their traditional onshore markets. Dr. Samaras holds a BSc with Honours in Pathology and Immunology from Monash University and a PhD from the Department of Medicine at The University of Melbourne. He also holds postgraduate business qualifications which include an MBA from the School of Management at RMIT University and is a Fellow of the Australian Institute of Company Directors. Special responsibilities: Non-Executive Chairman; Chairman Nomination and Remuneration Committee; Chairman Audit & Risk Committee Directorships of other listed companies: Nil Interests in shares and options: 2,024,016 ordinary shares Name: John R Melki Qualifications: BSc (Hons), PhD Experience: Dr. Melki has led the commercialisation efforts of Genetic Signatures as Chief Executive Officer since 2011. Dr. Melki originally joined Genetic Signatures in 2003 where he was responsible for leading the commercialisation of two research products (worldwide) and five diagnostic products (locally and Europe) in the role of Senior Principal Research Scientist. He has authored over 20 peer-reviewed articles and is listed as an inventor on eight patent applications. Dr. Melki received his BSc from the University of New South Wales and his PhD from the University of Sydney, where his thesis was awarded the Peter Bancroft Prize from the Medical School. His primary research focus was in the sodium bisulphite conversion of DNA which is at the core of Genetic Signatures’ 3base™ technology. Special responsibilities: Managing Director and Chief Executive Officer Directorships of other listed companies: Nil Interests in shares and options: 1,096,000 ordinary shares, 550,000 options over ordinary shares for the financial year ended 30 June 2021